Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Morgan Stanley increased its 12-month price target for Chemours Co. to $17 from $15 while keeping an Equalweight rating, citing higher valuation multiples among comparable companies - notably in the Thermal & Specialized Solutions (TSS) segment - even as it trimmed its own EBITDA projections. The brokerage flagged weak recent free cash flow convers…
Mizuho reduced its price target on Jack In The Box to $18 from $20 while keeping a Neutral rating, pointing to first-quarter results and reiterated fiscal 2026 guidance that show limited same-store sales growth, constrained unit expansion and unclear margin recovery. The chain reported soft top-line and transaction trends in the quarter, and outsid…
Morgan Stanley reduced its price target for Autodesk to $350 from $385 but retained an Overweight rating, citing steady reseller channel checks that underpin a strong fourth quarter. The firm forecasts structural margin gains and robust free cash flow supported by a reported 92% gross profit margin, while attention turns to the company’s fiscal 202…
UBS reduced its price target for Accendra Health Inc. to $3.00 from $4.00 while retaining a Neutral rating, after reviewing the company's fourth-quarter results and 2026 guidance. Though fourth-quarter EBITDA aligned broadly with UBS expectations, the midpoints of 2026 EBITDA and free cash flow guidance came in slightly below the analyst's projecti…
UBS reduced its price target for Steven Madden (SHOO) to $42 from $43 and retained a Neutral rating. The bank expects the company to provide soft fiscal 2026 EPS guidance driven by weak private-label and Off-Price channel sales and higher-than-expected selling, general and administrative expenses. UBS projects fiscal 2026 EPS guidance between $2.00…
UBS increased its price target for Hilton Worldwide Holdings Inc. to $360 from $312 and kept a Buy rating after updating its model following Hilton's fourth-quarter results. The bank extended its valuation year to 2028, shifted to the upper end of a 17-19x EV/EBITDA multiple range, and cited higher unit growth estimates for fiscal 2026-2028. Hilton…
Mizuho increased its price objective on ONEOK Inc. to $89 from $82 while keeping a Neutral rating, revising near-term adjusted EBITDA forecasts and adding 2028-2029 guidance. The bank flagged limited visibility into some 2026 drivers but expects synergies from prior acquisitions to bolster earnings next year. The move comes as the stock trades near…
Analysts at Raymond James warn that companies seeking reimbursement for import duties imposed under President Trump's emergency tariffs face a difficult process. The Supreme Court found the use of a 1977 emergency powers law unlawful, while U.S. Customs and Border Protection has stopped collecting the invalidated levies but has not clarified refund…
Evercore ISI raised its price objective for Walmart Inc. to $135 from $130 and kept an Outperform rating, pointing to the retailer's strong digital expansion and faster growth in higher-margin businesses such as advertising and memberships. The firm trimmed near-term earnings estimates modestly to reflect liability claims, weaker other income and i…
Raymond James kept a Market Perform rating on Matador Resources (MTDR) but raised its price target to $59 from $49, pointing to recently announced natural gas marketing agreements that secure firm transport from the Permian to Gulf Coast markets and should materially boost realizations. The company has also added oil hedges for 2026, announced a qu…
H.C. Wainwright reiterated a Buy rating and a $230 price target for Insmed (INSM), citing earlier-than-expected 2026 Brinsupri revenue guidance above $1 billion as a constructive sign for payer access and initial launch performance. The firm keeps peak Brinsupri sales at more than $5 billion while awaiting clarity on potential expansion into COPD a…
H.C. Wainwright raised its price target on Vanda Pharmaceuticals to $24 from $22 and kept a Buy rating after the U.S. Food and Drug Administration approved Bysanti (milsaperidone) for certain indications in adults. The drugmaker, whose shares trade at $5.76, faces mixed signals as regulatory gains are coupled with a weak fourth-quarter financial pe…
H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a $620 price target, citing robust Rezdiffra adoption and high gross margins despite near-term gross-to-net resets and seasonal reverifications. Madrigal reported mixed fourth-quarter 2025 results with revenue beating expectations but a sizable EPS shortfall, and Truist…
H.C. Wainwright reaffirmed its Buy rating and $2.00 price target on reAlpha Tech Corp. (NASDAQ:AIRE), highlighting recent acquisitions and modeling that suggests a material revenue uplift in 2026. The firm noted the stock's steep decline over the past year and identified potential upside tied to improved mortgage market dynamics and operational sca…
PTC Therapeutics is transitioning from royalty receipts to product-led growth centered on Sephience (PKU). With a market cap near $5.7B, strong free cash flow generation and an undemanding EV/EBITDA multiple, PTCT offers a structured long opportunity: entry $70.60, target $95.00, stop $58.00, trade horizon 180 trading days.
Bank of England policymaker Alan Taylor said high U.S. import tariffs appear set to remain and that the full economic effects will likely take many years to materialize. He noted recent U.S. actions that imposed a global levy after the Supreme Court voided earlier tariffs, observed signs of Chinese export diversion to other markets with potential d…
RBC Capital Markets upgraded Banco Santander to outperform from sector perform and raised its price target to €12.25 from €8.50 ahead of the bank’s Investor Day on Feb. 25. The brokerage’s revised view rests on a projected improvement in return on tangible equity, a planned self-help cost reduction, and substantial shareholder distributions under a…
BofA Securities trimmed its price objective on Dell Technologies to $135 from $150 while retaining a Buy rating. The firm raised its forecast for memory cost inflation substantially, driving a meaningful recalculation of margin and earnings impacts for fiscal 2027. BofA nonetheless believes Dell is better positioned than many peers to absorb elevat…
Guggenheim reduced its price target on Acadia Healthcare to $22 from $27 while keeping a Buy rating, cutting its 2026 EBITDA forecast to $566 million to reflect regulatory headwinds and raising its year-end 2026 leverage estimate to roughly 4.4x amid recent lawsuit developments. Leadership changes and additional analyst downgrades further underscor…
Guggenheim cut its target price for SentinelOne Inc to $24 from $28 but maintained a Buy rating, citing upside to near-term revenue and ARR estimates even as field checks produced mixed signals. The company faces executive turnover with CFO Barbara Larson leaving, and the stock trades near its 52-week low despite double-digit revenue growth.
Guggenheim reduced its price target on Genmab A/S (GMAB) to $40 from $45 while retaining a Buy rating, pointing to fiscal 2026 guidance that came in below Wall Street expectations. The company delivered revenue beats for 2025 but reported EPS below forecasts and issued product guidance for Epkinly and Tivdak that left room for investor concern. Gen…
BofA Securities increased its price target for Calumet Specialty Products Partners to $33 from $28 while retaining a Buy rating, citing stronger margins in renewable diesel and sustainable aviation fuel that underpin the value of Calumet's Montana Renewables business. The firm left most underlying estimates intact after updating its commodity assum…
On February 19, 2026, CNX Resources director Bernard Lanigan Jr. sold 46,119 shares of common stock for roughly $1.87 million after exercising options to acquire the same number of shares. The stock has climbed sharply over the past six months and was trading near its 52-week high at the time of the sale. Separately, CNX reported fourth-quarter 202…
U.S. stock futures traded lower Monday as investors weighed renewed trade uncertainty following a Supreme Court decision on emergency tariffs. Several notable premarket movers included a steep decline for Novo Nordisk after a failed obesity drug trial, gains for Eli Lilly and Domino’s Pizza, and a large rally in Arcellx after a takeover agreement w…
Finnish quantum computing company IQM has agreed to merge with special purpose acquisition company Real Asset Acquisition Corp., a move that would bring the startup to the New York Stock Exchange with an initial equity valuation of $1.8 billion. The transaction, contingent on shareholder and regulatory approvals, is targeted to close around June, w…
